Hemera Biosciences LLC

Hemera Biosciences LLC is a biotechnology startup based in the United States, founded in 2010. The company is focused on developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration (AMD). Their slogan succinctly captures their mission: "Developing HMR59, an intravitreal gene therapy, to preserve vision in eyes with dry age-related macular degeneration." As a clinical stage gene therapy company, Hemera is driven by the frustration experienced by physicians and scientists in their inability to provide treatment for patients with macular degeneration. Their solution is the gene therapy HMR59, which is currently undergoing FDA clinical trial testing as a one-time treatment for both the dry and wet forms of AMD. Notably, the therapy is administered during a routine office visit with the goal of preserving vision that will endure the life of the patients. The company's last recorded investment was a $1.30M Venture Round investment on 01 April 2013. The investors associated with this round are not specified in the available information. As venture capital analysts, it's important to consider the potential of Hemera Biosciences LLC in addressing a significant unmet medical need and the progress of their clinical trials in evaluating the attractiveness of their investment opportunity.